-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93

Benzinga·07/20/2026 12:38:13
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $95 to $93.